NCT03219710View on ClinicalTrials.gov

"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
DRUG

Ondansetron

Ondansetron will be given at a dosage of 0.15mg/kg IV/PO q8h.

DRUG

Dexamethasone

Dexamethasone will be given as 3mg/m2 IV/PO q8h.

DRUG

Aprepitant

Aprepitant will be given as per the weight. weight (15-40kg) - Day1 to Day 3 - 80 mg PO weight (\>40 kg) - Day 1 -125mg , Day 2 \& Day 3 - 80 mg PO

DRUG

Olanzapine

olanzapine will be given as 0.14mg/kg PO (rounded off to nearest 2.5 mg )

Trial Locations (1)

110029

Dr Bra Irch, Aiims, New Delhi, New Delhi

All Listed Sponsors
lead

All India Institute of Medical Sciences

OTHER

NCT03219710 - "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)" | Biotech Hunter | Biotech Hunter